Junrong Yan

Nanjing, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 51 publications

Exploratory genomic stratification of benefit from first-line immunotherapy-based combination in advanced biliary tract cancer: a biomarker analysis of a randomized phase 2 trial.

Exploratory genomic stratification of benefit from first-line immunotherapy-based combination in advanced biliary tract cancer: a biomarker analysis of a randomized phase 2 trial.

Journal: Frontiers in immunology
Published: May 12, 2026

ZR2-miniCHOP for elderly patients with newly diagnosed diffuse large B-cell lymphoma.

ZR2-miniCHOP for elderly patients with newly diagnosed diffuse large B-cell lymphoma.

Journal: BMC cancer
Published: January 08, 2026

Therapeutic misalignment averted by clonal evolutionary evidence: molecular confirmation of hepatic metastasis in SMARCA4-deficient non-small cell lung cancer initially misdiagnosed as resectable cholangiocarcinoma.

Therapeutic misalignment averted by clonal evolutionary evidence: molecular confirmation of hepatic metastasis in SMARCA4-deficient non-small cell lung cancer initially misdiagnosed as resectable cholangiocarcinoma.

Journal: Frontiers in oncology
Published: November 12, 2025

Molecular features influencing clinical outcome of advanced HER2-positive gastric cancer receiving trastuzumab plus chemotherapy.

Molecular features influencing clinical outcome of advanced HER2-positive gastric cancer receiving trastuzumab plus chemotherapy.

Journal: Annals of medicine
Published: November 06, 2025

Multimodal deep learning for survival prediction and biomarker discovery in non-small cell lung cancer.

Multimodal deep learning for survival prediction and biomarker discovery in non-small cell lung cancer.

Journal: BioData mining
Published: November 06, 2025

Molecular and immune determinants of response in locally advanced deficient DNA mismatch repair/microsatellite instability-high gastric or gastroesophageal junction adenocarcinoma treated with neoadjuvant chemoimmunotherapy.

Molecular and immune determinants of response in locally advanced deficient DNA mismatch repair/microsatellite instability-high gastric or gastroesophageal junction adenocarcinoma treated with neoadjuvant chemoimmunotherapy.

Journal: Cell communication and signaling : CCS
Published: October 02, 2025

Genomic alterations and dynamic molecular residual disease monitoring predict pathological response to neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma.

Genomic alterations and dynamic molecular residual disease monitoring predict pathological response to neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma.

Journal: Frontiers in immunology
Published: August 08, 2025

Plasma-Based Genomic Features Influencing Outcomes of T790M-Positive Non-Small Cell Lung Cancer Receiving Osimertinib.

Plasma-Based Genomic Features Influencing Outcomes of T790M-Positive Non-Small Cell Lung Cancer Receiving Osimertinib.

Journal: Cancer medicine
Published: April 18, 2025

Genomic profiles and prognostic biomarkers of resectable lung adenocarcinoma with a micropapillary component.

Genomic profiles and prognostic biomarkers of resectable lung adenocarcinoma with a micropapillary component.

Journal: Frontiers in oncology
Published: February 28, 2025

Multi-omics analysis uncovers predictive biomarkers for the efficacy and outcomes of chemoimmunotherapy in advanced unresectable biliary tract cancers.

Multi-omics analysis uncovers predictive biomarkers for the efficacy and outcomes of chemoimmunotherapy in advanced unresectable biliary tract cancers.

Journal: BMC medicine
Published: September 28, 2024

Sintilimab and anlotinib with gemcitabine plus cisplatin in advanced biliary tract cancer: SAGC a randomized phase 2 trial.

Sintilimab and anlotinib with gemcitabine plus cisplatin in advanced biliary tract cancer: SAGC a randomized phase 2 trial.

Journal: Nature communications
Published: June 10, 2024

Changing ALK-TKI mechanisms of resistance in re-biopsies of ALK-rearranged NSCLC: ALK mutations followed by SCLC-like histologic transformation: A case report.

Changing ALK-TKI mechanisms of resistance in re-biopsies of ALK-rearranged NSCLC: ALK mutations followed by SCLC-like histologic transformation: A case report.

Journal: Heliyon
Published: February 08, 2024
Showing 1-12 of 51

Last Updated: 09/26/2026